Home
Granules India Ltd Board of Directors
Board of Directors at Granules India Ltd
Non-Exec. & Independent Dir.
Chairman & Managing Director
Company Sec. & Compli. Officer
Executive Director
Non-Exec & Non-Independent Dir
Key Highlights
- C Krishna Prasad continues to serve as the Chairman & Managing Director in 2024, maintaining the same position as in the previous year.
- Harsha Chigurupati continues to serve as the Executive Director in 2024, maintaining the same position as in the previous year.
- Uma Devi Chigurupati continues to serve as the Executive Director in 2024, maintaining the same position as in the previous year.
- K B Sankara Rao continues to serve as the Non-Exec & Non-Independent Dir in 2024, maintaining the same position as in the previous year.
- Chaitanya Tummala joins the board as Company Sec. & Compli. Officer, in a new position in 2024. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.

Granules India Ltd
NSE: GRANULES
Share Price
Last Ten Days Market Price
Date | |
---|---|
22 Apr 2025 | 480.5 |
21 Apr 2025 | 480.45 |
17 Apr 2025 | 467.4 |
16 Apr 2025 | 462.6 |
15 Apr 2025 | 464.35 |
11 Apr 2025 | 452.1 |
09 Apr 2025 | 431.2 |
08 Apr 2025 | 444.65 |
07 Apr 2025 | 436.8 |
04 Apr 2025 | 457.2 |
Company Fundamentals for Granules India Ltd
Market Cap
11,654 Cr
EPS
19.8
P/E Ratio (TTM)
24.3
P/B Ratio (TTM)
3.4
Day’s High
483.85
Day’s Low
474.55
DTE
0.3
ROE
14.2
52 Week High
724.55
52 Week Low
389.15
ROCE
16.9
Market Price of Granules India Ltd
1M
1Y
3Y
5Y
Granules India Ltd News Hub
Granules India Ltd soars 1.63%, up for third straight session
Granules India Ltd rose for a third straight session today. The stock is quoting at Rs 686.45, up 1.
Read more
21 Aug 24
Granules Pharmaceuticals receives USFDA approval for Glycopyrrolate Oral Solution
Granules India announced today that the U.S. Food and Drug Administration (FDA) has approved its Abb
Read more
20 Aug 24
Granules India rises on USFDA nod for oral drug Glycopyrrolate
The ANDA has been filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary o
Read more
20 Aug 24
Granules India receives US FDA nod for depression treatment drug Trazodone
It is bioequivalent and therapeutically equivalent to the reference listed drug Desyrel Tablets of P
Read more
09 Aug 24